Delivery Order SPE2DB22D2108-SPE2DB25FU5TA
- Not listed
- The Defense Logistics Agency awarded a $1,944.90 delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL vials (10 mL) on July 18, 2025, with completion scheduled for July 21, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal vendor specializing in medical supply chain support for military and veteran healthcare...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of NovoLog 100 Unit/mL vials (10mL) with a ceiling value of $1,619.42. This firm fixed-price delivery order is non-competitive and represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.9 billion through December 2026. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a $3,362.46 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of NovoLog 100 Unit/mL vials (10mL), with an ultimate completion date of September 19, 2025. This contract was competitively awarded without set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,761.94 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL vials (10mL) on June 16, 2025, with an ultimate completion date of June 17, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $1,803.20 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for NovoLog 100 Unit/mL vials (10 mL units). This non-set-aside competitive award represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, serves as a critical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL) with a ceiling value of $1,040.41. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 29, 2025. This delivery order represents...
- The Defense Logistics Agency awarded a delivery order valued at $18,514.11 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL vials (10 mL) on August 26, 2025, with completion targeted for August 27, 2025. This firm fixed-price contract was awarded without set-aside designation through open competition. The award represents a delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL) with a ceiling value of $1,424.55. This competitive award, issued under a firm fixed-price delivery order contract type, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The order does not utilize a...
- The Defense Logistics Agency awarded a $1,275.43 delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL), an insulin product used in diabetes management. This firm fixed-price delivery order, with an ultimate completion date of August 13, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was made through open competition with no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $4,754.40 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL vials (10 mL) on September 3, 2025, with an ultimate completion date of September 4, 2025. The contract is structured as a firm fixed price delivery order with no set-aside designation, indicating competitive award status. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract...
- SPE2DB22D2108Indefinite Delivery Contract
- SPE2DB22D2108-SPE2DB25FU5TADelivery Order
The Defense Logistics Agency awarded a delivery order valued at $13,651.84 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL vials (10mL) on September 8, 2025, with completion targeted for September 9, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement extending through December 2026 that serves as the primary vehicle for global pharmaceutical support to military healthcare systems. AmerisourceBergen Drug Corp is a major pharmaceutical distributor providing critical medical commodities to federal healthcare programs, including the Defense Health Agency and U.S. Coast Guard. The company maintains an extensive portfolio of delivery orders through its DLA prime vendor contract, supplying a comprehensive range of medications across multiple therapeutic domains. This NovoLog insulin delivery supports ongoing military and veteran healthcare requirements, consistent with the company's demonstrated capability to meet federal procurement needs through open competition and its role as a key vendor within the DLA's Pharmaceutical Prime Vendor program.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.7k | 9/8/25 |